Searching...
12 results for “undruggable targets”
...like two fifty three that so many companies try to target and no one really managed to get to molecules that really works or, like, it worked, but the target product profile wasn't desirable. Yeah. I think until we clear out that list, there's defini
29:57 / 31:01
from transcript29:57 – 31:01
This is targeting the toughest diseases produced by Bloomberg Media Studios and Vertex Pharmaceuticals. In this series, we look at some of humanity's most challenging diseases and how Vertex, a Boston based biotech company, is using innovative tools,
1:29 / 2:34
from transcript1:29 – 2:34
She's the vice president and disease area executive for type one diabetes at Vertex. They are researching type one diabetes at the cellular level, something she first got interested in when she was a student. It was really a lecture that I saw when I
9:43 / 10:47
from transcript9:43 – 10:47
of one of the pharma companies that we can make. Exactly. How many of these rare diseases are there out there that people need help with? Like, is it is it, I don't know, a couple thousand? I mean, how long will it take to chew through them? An incre
45:45 / 46:52
from transcript45:45 – 46:52
...hit those targets, by the way, in a whole array of new creative ways. So we have small molecules, the natural products that we got from boiling leaves, as you said earlier, like those have gotten you know, we're getting really good at designing smart
34:26 / 35:32
from transcript34:26 – 35:32
...new targets that we're going to unlock and entire markets that we can open up and therapeutics we can get to patients to real really cure diseases that have had no cure before, that's just an incredibly exciting prospect for us. I wanna come back to
9:45 / 10:59
from transcript9:45 – 10:59
modalities, like the gene therapies of the world or the gene editors of the world. And when you can do that and combine that with our ability to hopefully use things like virtual cell models to really understand what to go after, like we're gonna hav
35:07 / 36:18
from transcript35:07 – 36:18
...it targets a different part of the influenza virus.
1:25:29 / 1:26:32
from transcript1:25:29 – 1:26:32
at the stage of, biotech development where we really need something like that to incentivize development of drugs for age related diseases or for longevity itself. Right now, age related indications have some of the highest failure rates in terms of
48:01 / 49:10
from transcript48:01 – 49:10
And the key for that is that you could then look at what mechanisms are turned on and off in any one disease during that trajectory and what's the subset of people that you should choose to homogeneously test your hypothesis or a drug such that the o
30:44 / 31:57
from transcript30:44 – 31:57
about it. And I think that's why investing in in the product layer here is really important. And not to mention, it's only gonna get more complicated from here. Right? As we start to support more advanced drug modalities, as there's various propertie
34:33 / 35:36
from transcript34:33 – 35:36
The area we are working on, just so you know, is that we can do better at understanding the state of a particular patient. Like right now, people say stage one cancer, stage two cancer, as though there's such a thing. The medical profession has creat
30:02 / 31:08
from transcript30:02 – 31:08
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.